Board of Directors
 |
Verna Skanes (Chair) Verna Skanes remains associated with Memorial University of Newfoundland as Adjunct Professor of Medicine since her retirement in 1999. She is currently serves on the Advisory Board of the Institute for Circulatory and Respiratory Health, and the Selection Committee of the Networks of Centres of Excellence Program. |
 |
George Daley George Daley is the Immediate Past President of the International Society for Stem Cell Research, Associate Director of the Stem Cell Program at Children’s Hospital, and a member of the Executive Committee of the Harvard Stem Cell Institute. Dr. Daley received his bachelor's degree magna cum laude from Harvard University, a Ph.D. in biology from MIT, and his M.D. summa cum laude from Harvard Medical School. He is a fellow of the American Association for the Advancement of Science, a member of the American Society for Clinical Investigation, and has received the NIH Director’s Pioneer Award, the Judson Daland Prize from the American Philosophical Society, and research awards from Harvard Medical School, the National Institutes of Health, the New England Cancer Society, the Burroughs-Wellcome Fund, the Edward Mallinckrodt, Jr. Foundation, and the Leukemia and Lymphoma Society of America. |
 |
Dr. Christian Detellier Christian Detellier has been at the University of Ottawa since 1981, and currently serves as the Associate Vice-President, Research. He has served on the editorial boards of Supramolecular Chemistry from 1992 to 2000 and of l' Actualité Chimique Canadienne/ Canadian Chemical News from 1991 to 95. He is a member of the Editorial Advisory Board of The Canadian Journal of Chemistry (2007-2010). He joined the Board of Directors of the Chemical Institute of Canada (2006-09; vice-Chair 2006-07; Chair 2007-08; Past Chair 2008-09), was elected to the Council of the International Clay Minerals Society (2009-12) and was the founding chair of the Steering committee of the National UltraHigh Field NMR Facility for Solids and Materials. He has authored or co-authored more than 140 research papers. |
 |
Allen Eaves Allen Eaves has been a Professor in the departments of Medicine and Pathology at the University of British Columbia since 1988. He founded the Terry Fox Lab in 1981, and has since served as the lab's Director. Dr. Eaves has been the recipient of many awards and distinctions. |
 |
Frank Gleeson Frank Gleeson has 20 years of leadership and business building experience; throughout his career he has completed over $500 million in financing and partnering transactions. Most recently Frank served as President and CEO of The Williamson Group, a 50 person professional services firm. Frank spent 5 years as a venture capitalist with MDS Capital Corp. as a Senior Vice-President and Partner. Before MDS, Frank had a 16-year career with ICI plc both in Canada and the U.K. Frank holds B.B.A. and M.B.A. degrees from York University in Toronto. |
 |
Yvan Guindon Yvan Guindon is a member of the Department of Chemistry at McGill University and became a Fellow of the Chemical Institute of Canada in 1988. He is also a member of the Royal Society of Canada, and a member of the Order of Canada. He completed his Ph.D. studies in 1981 at the Université de Montréal. He is the former Senior Director at Merck Frosst Canada and Vice President of Bio-Mega/Boehringer Ingelheim Research. |
 |
Gary Levy Gary Levy heads a research group of 11 principle investigators which is focused on immune-mediated mechanisms of organ injury due to viruses, alloantigens, and xenoantigens. He has published over 250 original articles, books and book chapters. He served as the Chief Scientific Officer of Transplantation Technologies Inc., from 1997 to 2002. He was recently awarded the Canadian Liver Foundation Commemorative Medal for the Queen's Jubilee for his contribution to liver disease in Canada. |
 |
Geoff MacKay Geoff MacKay has served in his current leadership role at Organogenesis Inc. since Dec. 2003, providing the company with significant global, commercial experience spanning the pharmaceutical and biotechnology sectors. Mr. MacKay has held numerous leadership positions within Novartis AG in roles such as Vice-President & Business Unit Head, Transplantation & Immunology at Novartis Canada, Vice-President of Tissue-Engineering in Novartis USA, Head of Global Sales Immunology & Transplantation based in Basel, Switzerland, and prior to that as Sales & Marketing Manager of Novartis Biotech Europe. Mr MacKay has been specifically involved in the emerging field of Regenerative Medicine for the last decade. |
 |
J. Andrew McKee Andrew McKee, prior to his appointment as the President and CEO of the Juvenile Diabetes Research Foundation (JDRF), was an active volunteer and board member for nearly 15 years, serving most recently as the Foundation’s Vice Chairman and Treasurer. With a strong focus on corporate responsibility and stakehol der value creation, Andrew remains an active investor in several companies engaged in Juvenile Products Distribution, Satellite Technologies, Environmental Technologies, Recreation, Property Development and Oil & Gas. Andrew is currently a Governor of the Royal Agricultural Winter Fair and sits on their Finance Committee. |
 |
Fabio Rossi Fabio Rossi obtained his M.D. in Genoa, Italy. During medical school, he developed a passion for the investigation of the complex biological mechanisms underlying tissue regeneration. Next, he joined the Ph.D. program at the European Molecular Biology Laboratories in Heidelberg, Germany, where he investigated how leukemia viruses deregulate growth and impose changes on the mature functions of infected cells under Thomas Graf’s supervision. His postdoctoral training took place at Stanford University with Helen Blau, where he became interested in the biology of muscle regeneration. He holds a Canada Research Chair in regenerative medicine and funding from multiple federal sources and charities. His main research interests span embryonic and adult stem cell physiology, and in particular how multiple types of stem cells coordinate their actions to regenerate complex tissues. |
 |
Michael Rudnicki Michael Rudnicki is Senior Scientist and Director of Molecular Medicine at the Ottawa Health Research Institute, Canada Research Chair in Molecular Genetics, professor at the University of Ottawa, and Scientific Director of the Ottawa Genome Centre. Dr. Rudnicki's laboratory is responsible for the milestone identification of the Pax7 protein that triggers stem cell specification into muscle cells. |
 |
Robert Young Robert Young earned a B.Sc. from the University of Victoria, a Ph.D. from the University of British Columbia, and continued postdoctoral studies at the Imperial College of Science and Technology, the University of Adelaide and the University of British Columbia. Dr. Young has served as Research Associate at the Institut de Chimie des Substances Naturelles in Gif-sur-Yvette, France, and has worked in various capacities with Merck Frosst Canada & Co. His current research is focused on the design and use of novel pharmacological probes and proof of concept molecules for the discovery and validation of new drug targets. He is also co-director of the Division of Design and Synthesis of the Center for Drug Research and Development in British Columbia and consults for a number of Pharmaceutical companies through his own company, Promorpheus Consultants Inc. Dr. Young is a member of the Order of Canada and a Fellow of the Royal Society of Canada and Fellow of the Chemical Institute of Canada. |
 |
Laurie Zoloth Laurie Zoloth is past President of the American Society for Bioethics and Humanities. She is a member of the Executive Committee of the International Society for Stem Cell Research, and she is the Chair of the Howard Hughes Medical Institute's Bioethics Advisory Board. Her current research projects include work on the emerging issues in medical and research genetics, and on the ethical issues in stem cell research, and her research interest in distributive justice in health care continues. She has been awarded three faculty recognition awards at SFSU, for teaching large classes, for research, and for community service. In 2000 she was awarded a NIH ELSI (Ethical Legal and Social Issues of the Human Genome) Grant to explore the ethical issues after the mapping of the human genome. |